SK Biopharmaceuticals expands DTx for epilepsy…”Synergy with new drugs”
Reporter Eom Eun-hyuk of Biospectator Announcement of the digital health vision. ▲ Hwang Seon-gwan, Vice President of SK Biopharmaceuticals SK Biopharmaceuticals has officially announced its expansion into the digital therapeutics (DTx) market by managing the “Project ZeroTM”, which aims to “completely eliminate seizures” in epilepsy. This is a fresh move three years after SK Biopharmaceuticals’ … Read more